Subscribe to CIO Magazine »

ASX-listed Alchemia appoints CFO to top post

Brisbane-based company promotes Charles Walker to CEO
ASX-listed Alchemia appoints CFO to top post

ASX-listed drug discovery company Alchemia (ASX:ACL) has promoted its CFO Charles Walker to CEO with immediate effect.

Walker, who has been with the Brisbane-based firm for the past two years as CFO, has 20 years’ experience in the life sciences industry, firstly as a pharmacologist in the UK before moving into the pharmaceutical industry. He then spent a decade in corporate finance advising international technology companies, and has executed more than 40 corporate transactions including mergers and acquisitions, IPOs and fundraising.

Another key achievement was co-founding a life sciences investment bank in the UK, which was sold to Nomura International in 2005. Walker replaces former CEO Dr Peter Smith, who resigned in January and has assumed a non-executive director’s post.

In a statement, Walker said he saw further opportunities for Alchemia’s fast-growing business in the late-stage drug development to internationalise under his leadership. The company owns the US Food and Drug Administration approved anticoagulant drug Fondaparinux as well as oncology products under its subsidiary Audeo Oncology.

Alchemia failed its bid for a US IPO for Audeo in late 2012, blaming investor concerns about the state of the US economy and market conditions, and stated it would re-evaluate longer-term financing options including a possible listing this year.

“The next 12 months will be transformative both in terms of clinical and corporate development and I am looking forward to building on the strong foundations already established, and continuing to work to unlock value for shareholders,” Walker said.

Follow CFO World Australia on Twitter: @CFOworld_AU, or take part in the CFO World conversation on LinkedIn: CFO World.

Join the CIO Australia group on LinkedIn. The group is open to CIOs, IT Directors, COOs, CTOs and senior IT managers.

More about: Alchemia, Nomura International
References show all
Comments are now closed.
Related Coverage
Related Whitepapers
Latest Stories
Community Comments
Tags: drug discovery, Alchemia, ASX, Charles Walker
Latest Blog Posts
  • Google+ Guide
    From “hangouts” to “communities,” Google+ has a lot to offer to brands looking to engage audiences and refine their strategies on this social platform. The Google+ Update, by Oracle Social Cloud (#OracleSocial), includes an overview of new features and functionality, user demographics, industry trends, and a review of best practices that will help increase the likelihood of user engagement and aid in a brand’s success in this channel.
    Learn more »
  • Simple, Proven, Tranformative
    A cheat Sheet for Google Apps for Business
    Learn more »
  • Don’t Rip and Replace - Wrap and Renew!
    The abundance of legacy applications in the contact centre can trap a business into rigid, inefficient processes and introduce undue complexity. A unified, omni-channel desktop can transform customer experience without the cost and complexity of rip and replace. This whitepaper explains how companies can save time and money by taking advantage of existing resources in a new way.
    Learn more »
All whitepapers
rhs_login_lockGet exclusive access to Invitation only events CIO, reports & analysis.
Latest Jobs
Salary Calculator

Supplied by

View the full Peoplebank ICT Salary & Employment Index

Recent comments